Livforsakringsbolaget Skandia Omsesidigt lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 125,464 shares of the company’s stock after selling 1,900 shares during the quarter. Johnson & Johnson accounts for 2.0% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 6th biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Johnson & Johnson were worth $18,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Newfound Research LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth about $28,000. Islay Capital Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $42,000. FAI Wealth Management lifted its stake in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares in the last quarter. Finally, HWG Holdings LP acquired a new position in shares of Johnson & Johnson in the second quarter worth about $49,000. Institutional investors own 67.44% of the company’s stock.
JNJ has been the topic of several recent analyst reports. Cantor Fitzgerald boosted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Credit Suisse Group boosted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $164.93.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
Shares of Johnson & Johnson stock opened at $146.36 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The firm has a market cap of $385.30 billion, a P/E ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The business has a 50-day moving average price of $145.51 and a 200 day moving average price of $146.57.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.12 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: What can cause a stock to outperform?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.